research Reconsidering the classification of vitiligo and alopecia as cosmetic concerns in Medicaid and Tricare policies
Vitiligo and alopecia should be covered by Medicaid and TRICARE as medical, not cosmetic, conditions.
Search
forResearch
5 / 1000+ results
research Journeying Through the Hurdles of Gender-Affirming Care Insurance: A Literature Analysis
Transgender individuals face insurance barriers to gender-affirming surgery, needing policy reforms for better access.
research Selling stem cells in Australia: assessing the impact of new advertising standards on business practices
New Australian advertising rules improved stem cell marketing practices but further regulation is needed for consumer safety.
research Addressing Autoimmune and Immune-mediated Skin Disease Burden in Women
The conclusion is that women are heavily affected by autoimmune skin diseases, face significant challenges, and need better research, treatments, and healthcare policies.
research Lifestyle Drugs
The article concludes that a balance is needed between individual healthcare needs and societal resources when it comes to lifestyle drugs, with a call for compassionate policy application.
Community Join
1 / 1000+ resultscommunity FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Learn
— no results
Experts
— no results
Clinics
— no results